A Comparative Study of Serum Adiponectin and Insulin Resistance In Patients With Polycystic Ovary Syndrome

Amena Arif; Robina  Anees; Amir  Rashid; Naeema  Ahmed

doi:10.51253/pafmj.v74i5.11360

Authors

Amena Arif Department of Biochemistry, Federal Medical College, Islamabad Pakistan
Robina Anees Islamabad Health Services Hospital Naval Anchorage, Islamabad Pakistan
Amir Rashid Department of Biochemistry, Army Medical College Rawalpindi /National University of Medical Sciences (NUMS) Pakistan
Naeema Ahmed Department of Biochemistry, Army Medical College Rawalpindi /National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i5.11360

Keywords:

Adiponectin, Homeostatic Model Assessment of Insulin Resistance, Insulin Resistance, Metabolic Syndrome, Polycystic Ovary Syndrome

Abstract

Objective: To assess correlation between serum adiponectin levels and insulin resistance in patients with Polycystic ovary syndrome.

Study Design: Comparative Cross-Sectional study.

Place and Duration of Study: PNS Hafeez Hospital, Islamabad Pakistan, and Multidisciplinary Lab-I, Department of Biochemistry, Army Medical College Rawalpindi, Pakistan from Feb 2018 to Jan 2019.

Methodology: Three groups (35 females each) were formed from selected one hundred and five females (puberty till 25 years) who had Polycystic ovary syndrome. After overnight fast, blood samples were collected to measure serum levels of insulin and adiponectin. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) was used to calculate insulin resistance.

Results: The over-weight PCOS subgroup displayed lowest serum adiponectin level (8.73±2.13 mg/L; 13.87±3.60 mg/L in normal weight PCOS and 15.09±3.07 mg/L in controls). There was statistical significance of serum Fasting Blood Glucose (mmol/L, p=0.002), serum Insulin (mIU/L; p=0.003) andserum Adiponectin levels (mg/L; p˂0.001) and HOMA-IR (p<0.001) among three groups. The over-weight PCOS subgroup presented with highest HOMA-IR (1.71±0.19; 1.35±0.25 in normal weight PCOS subgroup and 1.12±0.26 in controls). There is negative correlation between serum adiponectin and HOMA-IR with r= -0.46.

Conclusion: In PCOS-affected females, HOMA-IR correlates inversely with serum adiponectin levels, signifying that abdominal adiposity indirectly favors insulin resistance in PCOS through decrease in adiponectin secretion. Serum adiponectin level is negatively associated with severity of IR in PCOS.

Downloads

Download data is not yet available.

References

Manique ME, Ferreira AM. Polycystic Ovary Syndrome in Adolescence: Challenges in Diagnosis and Management. Rev Bras Ginecol Obstet 2022; 44(04): 425-433.

https://doi.org/10.1055/s-0042-1742292

Tay C, Hart R, Hickey M, Moran L, Earnest A, Doherty D, et al. Updated adolescent diagnostic criteria for polycystic ovary syndrome: Impact on prevalence and longitudinal body mass index trajectories from birth to adulthood. BMC Med 2020; 18(1): 1-1. https://doi.org/10.1186/s12916-020-01861-x

Yasmin A, Roychoudhury S, Paul Choudhury A, Ahmed A, Dutta S, Mottola F, et al. Polycystic ovary syndrome: An updated overview foregrounding impacts of ethnicities and geographic variations. Life 2022; 12(12): 1974.

https://doi.org/10.3390/life12121974

Barber TM, Joharatnam J, Franks S. Pathogenesis and management of adiposity and insulin resistance in polycystic ovary syndrome (PCOS). Pediatric obesity: Etiology, pathogenesis and treatment. 2018: 629-642.

https://doi.org/10.1007/978-3-319-68192-4

Kadhim SM, Al-Fartusie FS, Klichkhanov NK. Evaluation of Adiponectin and Hepcidin with some Biochemical Parameters in Sera of Women with Polycystic Ovary Syndrome. Al-Mustansiriyah J Sci 2023; 34(1): 52-57.

http://doi.org/10.23851/mjs.v34i1.1299

Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the pathogenesis, diagnosis and treatment of PCOS: Focus on insulin resistance, inflammation, and hyperandrogenism. Int J Mol Sci 2022; 23(8): 4110.

https://doi.org/10.3390/ijms23084110

Hernández-Jiménez JL, Barrera D, Espinoza-Simón E, González J, Ortíz-Hernández R, Escobar L, et al. Polycystic ovarian syndrome: Signs and feedback effects of hyperandrogenism and insulin resistance. Gynecol Endocrinol 2021; 38(1): 2–9. https://doi.org/10.1080/09513590.2021.2003326

Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab 2020; 35: 100937.

https://doi.org/10.1016/j.molmet.2020.01.001

Pal L, Pathy S. Polycystic ovarian syndrome. Evidence‐based Obstet Gynecol 2019:117-129.

https://doi.org/10.1002/9781119072980.ch12

Arif A, Waheed P, Anees R, Rashid A, Khan SA. A Comparative Study of Insulin Resistance in Patients of Polycystic Ovary Syndrome: Insulin Resistance in Polycystic Ovary Syndrome. Pak Armed Forces Med J 2021; 71(5): 1746-1750.

https://doi.org/10.51253/pafmj.v71i5.2633

Hussein SR, Sadiq AM, Johar SA, Nasrawi AJ. Insulin level, lipid profile, and HOMA index in lean and obese patients with polycystic ovary syndrome. J Med Life 2023; 16(8): 1258.

https://doi.org/10.25122/jml-2023-0040

HOMA-IR - insulin resistance calculator 2014. Available from: https://thebloodcode.com/homa-ir-calculator/ ( Accessed on January 29. 2019)

Khan MJ, Ullah A, Basit S. Genetic basis of polycystic ovary syndrome (PCOS): current perspectives. Appl Clin Genet 2019: 249-260.

http://doi.org/10.2147/TACG.S200341

Chen W, Pang Y. Metabolic syndrome and PCOS: Pathogenesis and the role of metabolites. Metabolites 2021; 11(12): 869. https://doi.org/10.3390/metabo11120869

Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health 2019; 13:1179558119874042.

https://doi.org/10.1111/j.1365-2265.2006.02587.x

Shirazi FK, Khodamoradi Z, Jeddi M. Insulin resistance and high molecular weight adiponectin in obese and non-obese patients with Polycystic Ovarian Syndrome (PCOS). BMC Endocr Disord 2021; 21(1): 1-7.

https://doi.org/10.1186/s12902-021-00710-z

Baldani DP, Skrgatic L, Kasum M, Zlopasa G, Kralik Oguic S, Herman M. Altered leptin, adiponectin, resistin and ghrelin secretion may represent an intrinsic polycystic ovary syndrome abnormality. Gynecol Endocrinol 2019; 35(5): 401-405.

https://doi.org/10.1080/09513590.2018.1534096

Amisi CA. Markers of insulin resistance in Polycystic ovary syndrome women: An update. World J Diabetes 2022; 13(3): 129. https://doi.org/10.4239/wjd.v13.i3.129

Borzan V, Lerchbaum E, Missbrenner C, Heijboer AC, Goschnik M, Trummer C, et al. Risk of insulin resistance and metabolic syndrome in women with hyperandrogenemia: a comparison between PCOS phenotypes and beyond. J Clin Med 2021; 10(4): 829.

https://doi.org/10.3390/jcm10040829